Figure 1. Prolongation of corneal allograft survival by topical administration. Allograft survival of the control versus topical 0.1%
FTY720 were not significantly different (p=0.47; n=9) but was compared with the topical 0.3% FTY720 treatment group (p=0.03;
n=9). Treatment with 0.5% FTY720 or 1% CsA also resulted in significant graft survival compared to controls (both p<0.01;
n=9) or 0.3% FTY720 treatment (p=0.02 and p=0.01, respectively). There was no significant difference between 0.5% FTY720 and
1% CsA (p=0.51).